Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology corporation, is pleased to announce that Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co., LLC (“Glass Lewis”), two leading independent proxy advisory firms, have recommended that shareholders vote FOR all items submitted for approbation by the shareholders, including the share consolidation for a potential Nasdaq listing and the Corporation’s name change, at the annual and special meeting of shareholders to be held on May 1, 2018.
Although the approval of shareholders for the share consolidation is being sought at the meeting, the share consolidation would become effective at a date in the future to be determined by the board, if and when it is considered to be in the best interest of the company to implement the share consolidation. The board may determine not to implement the share consolidation at any time after the meeting without further action on the part of, or notice to, the shareholders, and there is no assurance whatsoever that the common shares of the company will be listed on the Nasdaq.
ISS and Glass Lewis Share Consolidation Recommendations
Among their positive recommendations FOR all items on the agenda, ISS and Glass Lewis were of the view that the share consolidation allows for enhanced long-term growth prospects of the company by broadening its financing alternatives without impacting shareholder value. Accordingly, shareholders are encouraged to vote in favour of the share consolidation.
Attention Shareholders
Shareholders are reminded to vote their proxy before 10:00 a.m. (Eastern time), on April 27, 2018. Immunovaccine’s Board of Directors unanimously recommends that its shareholders vote FOR all items submitted for approbation of the shareholders, including the share consolidation and the name change.
For more information and assistance in voting your proxy, please contact Laurel Hill Advisory Group, at:
- North America toll-free: 1-877-452-7184
- Local and international: 416-304-0211
- Email: [email protected]
About Immunovaccine
Immunovaccine Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. Immunovaccine develops T cell-activating cancer immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology provides controlled and prolonged exposure to a broad range of immunogenic stimuli. Immunovaccine has advanced two T cell-activating therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1b study with Incyte Corporation assessing its lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer. The Company is also exploring additional applications of its platform, including DPX-RSV, an innovative vaccine candidate for respiratory syncytial virus (RSV), which has recently completed a Phase 1 clinical trial. Immunovaccine also has ongoing research projects in malaria and the Zika virus. Connect at www.imvaccine.com.
In the interest of full disclosure, we call the reader’s attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.
